The biopharmaceutical company doesn’t expect U.S. generic entry for the drug before 2037 now that it has settled litigation.

The news that the brand is protected from generics for more than a decade "gives AbbVie a kind of tremendous runway," to sell ...

AbbVie (NYSE:ABBV) announced on Thursday that the company has reached settlements with all generic drugmakers to resolve ...

Now, the Chicago pharma has done just that by striking a deal with a slate of generics manufacturers that waylays the entry ...

Biocon CEO Siddharth Mittal reveals plans to launch generic versions of diabetes drug Ozempic in key markets by the end of ...

In record-breaking operation, federal officials seized 4.7 million unauthorized e-cigarette products with an estimated retail ...

A generic formulation of Zeposia will be manufactured and supplied by Netherlands-based Synthon, upon final approval by the ...

Rapamycin is an immune suppressant often used in organ transplant patients, but it has also been shown to extend life in ...